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Faria, Leonardo Coutinho and Istvan Mody. Protective effect of
ifenprodil against spreading depression in the mouse entorhinal
cortex. J Neurophysiol 92: 2610–2614, 2004. First published June 16,
2004; 10.1152/jn.00466.2004. In the brain, spreading depression (SD)
is characterized by a large extracellular DC shift, a massive failure of
ion homeostasis and a transient cessation of neuronal function. Clin-
ically, SD is believed to be involved in various neurological disorders
including migraine and cerebrovascular diseases. The propagation of
cortical SD requires the release of glutamate, and N-methyl-D-aspar-
tate (NMDA) receptors play a crucial role in this process. Here, we
have isolated the NMDA receptor-mediated component of extracel-
lularly recorded field excitatory postsynaptic potentials (fEPSPs) in
layers 2–3 of the entorhinal cortex of murine brain slices. In the
absence of GABAA and AMPA receptor-mediated synaptic transmis-
sion, stimulation of layer 6 afferents every 15–90 s elicited sponta-
neous SD on average within 18.5 min after the start of the stimulation.
In the presence of ifenprodil, an NR2B receptor subunit-selective
NMDA receptor antagonist, the occurrence of SD was nearly abol-
ished. Our results are consistent with an important role of NR2B
subunits in triggering SD in the entorhinal cortex.
I N T R O D U C T I O N
Spreading depression (SD), first described by Lea˜o (1944),
is characterized by a large extracellular DC shift (do Carmo
and Somjen 1994), a massive failure of ion homeostasis, and a
transient cessation of neuronal function (Somjen 2001). SD can
be observed in most gray matter areas, but the hippocampal
CA1 region and the neocortex are especially prone to SD
(Somjen 2001). SD has been observed in vivo in different
species, including mammals (Krivanek 1976), and in vitro
brain slices (Snow et al. 1983). Both in vivo (Mayevsky et
al.1996) and in vitro (Avoli et al.1995) recordings from human
cortical tissue have shown SD activity. The association of SD
with various neurological disorders is well documented (Gorji
2001), but SD has been principally linked to migraine, cere-
brovascular diseases, head injury, and transient global amnesia.
The clinical relevance of SD has been dealt with by a recent
review (Gorji 2001).
The release of glutamate is essential to the propagation of
cortical SD (Van Harreveld and Fifkova 1973). Several studies
have shown that glutamate acts via N-methyl-D-aspartate re-
ceptors (NMDARs) during the generation and propagation of
SD (Gorelova et al. 1987; Marrannes et al.1988; McLachlan
1992; Mody et al. 1987). Antagonists of NMDARs block SD in
normal cortex, while non-NMDAR antagonists are ineffective
(Anderson and Andrew 2002). The efficacy of NMDA antag-
onists to block SD is further supported by several studies in
vivo (Koroleva et al. 1998; Lauritzen and Hansen 1992) and in
vitro (Footitt and Newberry 1998; Somjen 2001).
At first, NMDA antagonists were considered as having great
potential as neuroprotective agents (McCulloch 1994), but
most clinical trials have been disappointing as the drugs caused
psychomimetic and cardiovascular side effects severely limit-
ing their usefulness (Menniti et al. 2000). Nevertheless, spe-
cific subunit-selective NMDA antagonists may still preserve
neuroprotective properties without causing significant side ef-
fects (Menniti et al. 2000).
The NMDA receptor is a heterotetramer assembled from a
NR1 subunits and at least one subtype of the four members of
the NR2 (A–D) subunits family. The NR2A and NR2B sub-
units are predominantly expressed in the cortex and hippocampus
(Monyer et al.1992). Ifenprodil is part of a class of subunit-
selective NMDA receptor antagonists with high selectivity for
NR2B-containing receptors (Williams 1993). Its potency strongly
depends on extracellular pH and is only weakly affected by NR1
subunit splice variants(Pahk and Williams 1997).
A detailed characterization of the pharmacological proper-
ties of ifenprodil has been published (Grimwood et al. 2000).
Based on the role of NMDA receptors in the initiation and
propagation of SD (Mody et al. 1987), the aim of our study was
to identify possible subunit specificity in the process of SD
generation in the entorhinal cortex. Our findings are consistent
with a critical role of the NR2B subunits in the generation of
entorhinal cortical SD.
M E T H O D S
Animals
The experiments were performed on 22 adult (2–3 mo old) male
mice (Harlan, San Diego, CA, and Charles River Laboratories, Wil-
mington, MA). All experiments were carried out in accordance with a
protocol approved by the University of California Chancellors Animal
Research Committee conforming to the National Institutes of Health
guidelines on the ethical use of animals in research. Only the mini-
mum number of animals necessary to produce reliable scientific data
were used in this study.
Slice preparation
Horizontal slices containing the entorhinal cortex and the hip-
pocampus were obtained using standard technique (Gordey et al.
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2001). Briefly, mice were anesthetized with halothane and decapi-
tated. The brains were cooled to 4°C and rapidly removed, and whole
brain slices (350 m thick) were cut in the horizontal plane on a Leica
VT100S vibroslicer (Leica Microsystems, Deerfield, IL). After incu-
bating in artificial cerebrospinal fluid [ACSF, which contained (in
mM) 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2.0 CaCl2, 2.0 MgCl2, 26
NaHCO3, and 10 D-glucose] for 1 h in a storage chamber at 32°C,
the slices were transferred to another chamber containing low Mg (0.1
mM MgCl2), 50 M picrotoxin, 10 M glycine, and 10 M 6,7-
dinitroquinoxaline-2,3(1H,4H)-dione (DNQX), designed to isolate
NMDA field potentials (Crepel et al.1997; Dalby and Mody 2003;
Gordey et al. 2001). After 10–15 min, slices were transferred to a
recording chamber and continually perfused with the latter ACSF (2
ml/min, 34°C) in a atmosphere of humidified 95% O2-5% CO2.
Extracellular recordings
Evoked extracellular fEPSPs were recorded in layers 2–3 of the
entorhinal cortex. Constant current stimuli were delivered to layer 6 of
the entorhinal cortex every 15–90 s via bipolar tungsten stimulating
electrodes (Fig. 1A). NMDAR-mediated fEPSPs were isolated in the
presence of low-Mg2 plus 10 M DNQX and 50 M picrotoxin
(Gordey et al. 2001). Field potential recordings started after 10 min of
equilibration in the recording chamber. The amplitudes of NMDA
receptor-mediated fEPSPs were determined as the difference between
the baseline and the peak. The area was measured from the start of the
downward deflection of the fEPSP until the point when the field
potential returned back to the prestimulus baseline. For each experi-
ment, stimulation intensity was chosen to generate a standard ampli-
tude (0.7–1.0 mV) NMDA receptor-mediated field potential.
In our initial experiments, to obtain input-output curves, we
changed the widths of the stimuli while leaving the stimulus intensity
at a fixed current level. The stimulus widths ranged from 20 to 240 s
at intensities of 30–35 mA. Longer stimulus widths (140–240 s) led
to the appearance of SDs. In five input-output curves done in control
ACSF, SDs were induced three times with the stimulus widths of
140,160, and 240 s, respectively. Therefore in the experiments
presented here we used the stimuli had widths between 40 and 60 s.
Amplitude, duration and time to SD were also measured. The
amplitude of the SD peak was determined as the difference between
the baseline and the peak (as measured in fEPSPs). The duration of a
single SD was measured as the time elapsed between the start of the
negative deflection from baseline until the return of the DC field
potential to the same baseline. The time to SD occurrence was
measured from the time a stable extracellular response was obtained
until the first SD was recorded. We considered as an arbitrary cutoff
time for establishing the absence of SDs a period of 40 min. This time
corresponds to the average time of occurrence of SDs in control
ACSF  2 standard deviations.
Data sampling
Field potentials were amplified 100-fold through the headstage and
another two times through a BrownLee 440 Precision Amplifier (San
Jose, CA) and low-pass filtered (DC, 3 kHz, 4 pole Bessel) before
storing them on videotape (Neurocorder model PCM digitization at 88
kHz). Off-line, the recordings were replayed and low-pass filtered at
DC, 300 Hz (4 pole Bessel) before digitized (at 1 kHz) and stored on
a Pentium-processor-based PC using the in-house designed LabView
event detection and analysis (EVAN) software package.
Drugs
Stock solutions of 100 mM DNQX (Tocris, Ellisville, MO) and 100
mM ifenprodil (Sigma, St. Louis, MO) were prepared in 100%
dimethylsulfoxide (DMSO). For picrotoxin (Sigma), a 50 mM stock
solution was prepared in ethanol (95% vol/vol). DMSO or ethanol
alone in concentrations up to two times higher than in our experimen-
tal conditions did not alter NMDA receptor-mediated fEPSPs.
R E S U L T S
Properties of NMDA receptor-mediated fEPSPs
In the presence of a low-Mg2 ACSF containing DNQX and
picrotoxin, we recorded typical NMDAR-mediated fEPSPs
much like those observed in earlier studies in the hippocampus
and dentate gyrus (Dalby and Mody 2003; Gordey et al. 2001).
As shown in Table 1, the average peak amplitude of the
FIG. 1. Electrode positions and raw traces of field excita-
tory postsynaptic potentials (fEPSPs) and spreading depres-
sions (SDs). A: schematic representation of a combined hip-
pocampal/entorhinal cortical slice indicating the positions of
the extracellular electrodes. The recording electrode was posi-
tioned in layers 2–3, whereas the stimulating electrode was
placed in layer 6 of the entorhinal cortex. B: representative
averaged traces of evoked extracellular N-methyl-D-aspartate
fEPSPs showing similar properties in control artificial cerebro-
spinal fluid and after perfusion of a solution containing 10 M
ifenprodil. Bottom: the 2 traces superimposed indicating no
differences between the 2 averages. Vertical lines during the
SDs represent stimulus artifacts that were ineffective in evok-
ing field potentials. C: representative trace of a SD event
observed in trace was similar between both groups as can be
seen in control (D) or in 11 of 15 slices under control condi-
tions. D: raw trace of the SD observed in only 1 of 7 slices in
the presence of ifenprodil.
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NMDAR-mediated fEPSPs was 1.42  0.58 (SD) mV (n 
15) and their area was 944.1  584.4 mV/ms (n  15).
Perfusion of ifenprodil (10 M) did not change the properties
of NMDA fEPSP Fig. 1B and Table 1).
In three experiments, we compared the properties of NMDA
fEPSPs before and after perfusion of 10 M ifenprodil. Values
of area, peak, and decay time constants were measured in an
average of at least three traces (evoked every 15 s) in the
control solution and 10 min after the start of ifenprodil perfu-
sion and were found not to be significantly different between
the two conditions. The areas of fEPSPs in control and in
ifenprodil solution were, respectively (in mV/ms), 399.3 
56.5 and 424.7  145.7 (P  0.31, paired t-test), the peak
amplitudes were (in mV) 0.78  0.27 and 0.80  0.28 (P 
0.44, paired t-test), and the decay time constants were (in ms)
597.9 79.5 and 536.5 78.5 (P 0.56, paired t-test). These
findings, together with the group data presented in Table 1,
indicate the lack of effect of 10 M ifenprodil on the evoked
NMDA fEPSPs, consistent with being mediated by NR2A
containing receptors.
Induction of SD in isolated NMDAR-mediated
field potentials
While recording fEPSP mediated by NMDARs, we noticed
that spontaneous SDs developed within a certain time of the
recordings. SDs were observed in 11 of 15 slices (in as many
mice; frequency: 73.3%) at an average time of 18.5 11.6 min
after the start of the recordings, not counting the 10 min of
equilibration time in the recording chamber. If a brain slice did
not show SD after a recording period of 40 min, it was
considered not to have developed any SD. In two experiments,
we continued to record evoked responses beyond the 40-min
cutoff time, and observed no SDs at 60 and 80 min, respec-
tively.
As noted by previous investigators, SDs are characterized by
negative extracellular DC shifts reaching maxima of 30 mV
and a duration of0.5–1 min (Gorji 2001). In our experiments
in layers 2–3 of the entorhinal cortex, the average amplitude of
SD was 10.4 4.4 mV, whereas its duration was 51.6 29.3 s
(also see Table 1, and Fig. 1, C and D). During the SD, the
neurons of layers 2–3 were not responsive to electrical stimu-
lation, as no fEPSPs could be elicited for2 min after the start
of the SD. As shown in Fig. 1, C and D, a stimulus delivered
every 15 s could not evoke a response during the SD.
Frequently, more than three consecutive spontaneous SDs
could be recorded showing the reversible nature of neuronal
excitability after SD. The frequency of stimulation did not
appear to be a factor in the time required to induce SD. In two
slices, when the inter-stimulus interval was increased from 15
to 90 s, SDs developed within 20 and 26 min, respectively,
after the start of the stimulation.
SD fails to develop in the presence of ifenprodil
To address the specific contribution of NR2B receptors to
the generation of SD, we examined the induction of spontane-
ous SDs in the entorhinal cortex in the presence of the NR2B-
selective antagonist ifenprodil (10 M). In contrast to our
recordings without ifenprodil where SDs were induced in
11/15 slices, only one of seven slices developed SD in the
presence of ifenprodil. In this slice, SD occurred 7.4 min after
the start of the recording, and had peak amplitude of12.9 mV
and duration of 51.7 s.
Comparing the proportion of slices developing SDs in the
control and ifenprodil treated groups, the occurrence of SD was
significantly lower in the ifenprodil treated preparation (2 test;
df  1; 2  4.54, P  0.025). Interestingly, ifenprodil had no
significant effect on the peak and area of NMDAR-mediated
fEPSP (2-way ANOVA, P  0.05; Table 1).
D I S C U S S I O N
In the present study, we have recorded isolated fEPSPs
mediated by NMDA receptors in layers 2–3 of the murine
entorhinal cortex. Under our recording conditions with
AMPA/KA and GABAA receptors blocked, we have found no
specific contribution of NR2B subunits to evoked fEPSPs.
Nevertheless, these subunits were involved in the generation of
SD in entorhinal cortical slices, as the induction of SD was
nearly abolished in the presence of the NR2B subunit-specific
antagonist ifenprodil.
The properties of NMDA receptor-mediated fEPSPs in lay-
ers 2–3 of the entorhinal cortex recorded in the absence of
GABAA, AMPA/KA receptors were similar in the presence of
10 M ifenprodil, consistent with a lack of contribution of
NR2B subunits to the evoked synaptic potentials. These find-
ings were corroborated in experiments when the effect of
ifenprodil was tested on NMDA fEPSPs of the same slices. In
other brain regions, such as the hippocampal formation, exper-
iments using similar ifenprodil concentrations have revealed a
contribution of NR2B subunits to NMDA fEPSPs. In contrast
to the responses recorded in layers 2–3 of the entorhinal cortex,
isolated NMDA receptor-mediated fEPSPs in the dentate gyrus
and CA1 region of the hippocampus (Dalby and Mody 2003;
Gordey et al. 2001) had a reduced peak and a faster decay time
constant in 10 M ifenprodil. Thus the physiological mecha-
nisms responsible for generating fEPSPs and possibly the
localization of NR2B subunits at synapses are clearly different
between layers 2–3 of the entorhinal cortex and the hippo-
campus.
Another difference between the entorhinal cortex and the
hippocampus was the occurrence of SD. Previous studies using
similar methods (Dalby and Mody 2003; Gordey et al. 2001)
did not observe any SDs of isolated NMDA receptor-mediated
synaptic transmission in the hippocampus. In contrast, we
TABLE 1. Properties of fEPSPs and SDs observed in control
ACSF and in the presence of ifenprodil (10 M)
Control Ifenprodil, 10 M
fEPSP peak, mV 1.42  0.58 1.40 0.61
fEPSP area, mV  ms 944.1  584.4 860.4 660.9
Number of mice, slices 15 7
SD peak, mV 10.4  4.4 12.9
SD duration, s 51.6  29.3 51.7
Time to SD, min 18.6  11.6 7.4
Number of slices with SD 11 1*
Recordings were done in a single slice obtained from each experimental
animal. Numbers represent means  SD. fEPSP, field excitatory postsynaptic
potential; SD, spreading depression; ACSF, artificial cerebrospinal fluid. *sta-
tistically significant difference from control according to a 2 test; (df 1; P
0.025).
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frequently observed spontaneous SDs in the layer 2–3 of
entorhinal cortex when other ionotropic glutamate and GABAA
receptors were blocked. The amplitudes and durations of the
SDs recorded under these conditions in the entorhinal cortex
were not different from those recorded with intact AMPA/KA
receptors (McLachlan and Girvin 1994), indicating that the
NMDA receptors are critical in the both the generation and in
the shaping of SD waveforms. However
,
as both metabotropic
glutamate and GABAB receptors were intact in our experi-
ments, these receptors may have also contributed to the devel-
opment of SD. Our results using the specific NR2B receptor
antagonist ifenprodil argue against this latter possibility. Our
findings indicate that SDs generated in the entorhinal cortex
critically depend on the activation of NMDA receptors con-
taining ifenprodil-sensitive NR2B subunits. Previous studies
with NMDA antagonists are in accordance with our present
findings. The NR2B subunit antagonist, CP-101,606, a deriv-
ative of ifenprodil (Chenard et al. 1995) has been used to
investigate electrically induced cortical SD in rats in vivo
(Menniti et al. 2000). Cortical SDs were inhibited by this
compound in a dose-dependent fashion.
The results published by Somjen et al. (2000) validate the
dual hypothesis of van Harreveld (1978), who suggested the
existence of two kinds of SD: one mediated by glutamate and
the other by K. The conclusion is that besides channels
controlled by ionotropic glutamate receptors and TTX-sensi-
tive Na channels, other, as of yet unidentified, pathways can
mediate SD-like depolarizations. Recent computer simulations
performed by Kager et al. (2000, 2002) also suggest that more
than one agent can induce SD and that various ion channels can
provide the pathway for the ion fluxes underlying the depolar-
ization. An increase in extracellular level of [K]o and a
change in glial buffering power, can influence the ability to
generate SD.
The precise location of the NR2B subunits critically in-
volved in the generation of SD remains to be determined.
NR2B subunits appear to be present on presynaptic terminals
of entorhinal cortical neurons in acutely prepared brain slices
(Woodhall et al. 2001). Activation of these receptors may
enhance glutamate release, facilitating the occurrence of SDs.
Such presynaptic location of NR2B subunit-containing NMDA
receptors would also be consistent with the lack of an NR2B
receptor-mediated component in the synaptic field potentials.
Alternatively, predominantly extrasynaptically located NR2B
subunit-containing NMDA receptors (Tovar and Westbrook
1999) could generate large depolarization when activated by
ambient glutamate levels or when large glutamate overspill
occurs. It is interesting to note that the time to the occurrence
of SD in our slices was independent of the frequency of
stimulation, indicating that the amount of glutamate released
from the stimulated fibers was not a key factor in the occur-
rence of SD. A study by Tovar and Westbrook (1999) in cell
cultures showed predominantly synaptically localized NR2A
receptors and an extrasynaptic spread of NR2B receptor sub-
units. We cannot exclude the possibility that in other layers of
the entorhinal cortex NR2B subunit-containing NMDA recep-
tors may participate in synaptic events, and those sites may be
critically involved in the generation of SD.
Our studies have identified activation of NR2B subunit-
containing NMDA receptors as being critical for the induction
of SD in the entorhinal cortex. Notably, at therapeutically
effective doses in clinical trials, ifenprodil and its analogue
eliprodil did not share the significant side effects such as ataxia
and motor impairment of the nonsubtype-selective NMDA
receptor antagonists (Chizh et al. 2001). Thus our results
showing the dependence of cortical SD on NR2B subunit-
containing NMDA receptor activation may open specific phar-
macological approaches to the treatment of neurological dis-
orders thought to involve SD.
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